Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Antihypertensive Treatment in Acute Cerebral Hemorrhage
Antihypertensive Treatment in Acute Cerebral Hemorrhage (ATACH)
Status: Enrolling
Updated:  11/17/2017
JFK Medical Center
mi
from
Edison, NJ
Antihypertensive Treatment in Acute Cerebral Hemorrhage
Antihypertensive Treatment in Acute Cerebral Hemorrhage (ATACH)
Status: Enrolling
Updated: 11/17/2017
JFK Medical Center
mi
from
Edison, NJ
Click here to add this to my saved trials
Antihypertensive Treatment in Acute Cerebral Hemorrhage
Antihypertensive Treatment in Acute Cerebral Hemorrhage (ATACH)
Status: Enrolling
Updated:  11/17/2017
University of Medicine and Dentistry of New Jersey
mi
from
Newark, NJ
Antihypertensive Treatment in Acute Cerebral Hemorrhage
Antihypertensive Treatment in Acute Cerebral Hemorrhage (ATACH)
Status: Enrolling
Updated: 11/17/2017
University of Medicine and Dentistry of New Jersey
mi
from
Newark, NJ
Click here to add this to my saved trials
Antihypertensive Treatment in Acute Cerebral Hemorrhage
Antihypertensive Treatment in Acute Cerebral Hemorrhage (ATACH)
Status: Enrolling
Updated:  11/17/2017
Columbia University Medical Center
mi
from
New York, NY
Antihypertensive Treatment in Acute Cerebral Hemorrhage
Antihypertensive Treatment in Acute Cerebral Hemorrhage (ATACH)
Status: Enrolling
Updated: 11/17/2017
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Antihypertensive Treatment in Acute Cerebral Hemorrhage
Antihypertensive Treatment in Acute Cerebral Hemorrhage (ATACH)
Status: Enrolling
Updated:  11/17/2017
Case Western Reserve Univ
mi
from
Cleveland, OH
Antihypertensive Treatment in Acute Cerebral Hemorrhage
Antihypertensive Treatment in Acute Cerebral Hemorrhage (ATACH)
Status: Enrolling
Updated: 11/17/2017
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Antihypertensive Treatment in Acute Cerebral Hemorrhage
Antihypertensive Treatment in Acute Cerebral Hemorrhage (ATACH)
Status: Enrolling
Updated:  11/17/2017
Ohio State University
mi
from
Columbus, OH
Antihypertensive Treatment in Acute Cerebral Hemorrhage
Antihypertensive Treatment in Acute Cerebral Hemorrhage (ATACH)
Status: Enrolling
Updated: 11/17/2017
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Antihypertensive Treatment in Acute Cerebral Hemorrhage
Antihypertensive Treatment in Acute Cerebral Hemorrhage (ATACH)
Status: Enrolling
Updated:  11/17/2017
Statistical Coordinating Center: Medical University of South Carolina
mi
from
Charleston, SC
Antihypertensive Treatment in Acute Cerebral Hemorrhage
Antihypertensive Treatment in Acute Cerebral Hemorrhage (ATACH)
Status: Enrolling
Updated: 11/17/2017
Statistical Coordinating Center: Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Antihypertensive Treatment in Acute Cerebral Hemorrhage
Antihypertensive Treatment in Acute Cerebral Hemorrhage (ATACH)
Status: Enrolling
Updated:  11/17/2017
Saint Louis University
mi
from
Saint Louis, MO
Antihypertensive Treatment in Acute Cerebral Hemorrhage
Antihypertensive Treatment in Acute Cerebral Hemorrhage (ATACH)
Status: Enrolling
Updated: 11/17/2017
Saint Louis University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
The Emotion Builder: An Intervention for Emotional Deficits After Brain Injury
The Emotion Builder: An Intervention for Emotional Deficits After Brain Injury
Status: Enrolling
Updated:  11/20/2017
Indiana University Health Facilities
mi
from
Indianapolis, IN
The Emotion Builder: An Intervention for Emotional Deficits After Brain Injury
The Emotion Builder: An Intervention for Emotional Deficits After Brain Injury
Status: Enrolling
Updated: 11/20/2017
Indiana University Health Facilities
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer
Effects of Chemotherapy on Brain Structure and Function
Status: Enrolling
Updated:  11/21/2017
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer
Effects of Chemotherapy on Brain Structure and Function
Status: Enrolling
Updated: 11/21/2017
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
TWILIGHT Study: Effect of Light Exposure During Acute Rehabilitation on Sleep After TBI
TWILIGHT: Effect of Light Exposure During Acute Rehabilitation on Sleep After TBI.
Status: Enrolling
Updated:  11/21/2017
Harborview Medical Center
mi
from
Seattle, WA
TWILIGHT Study: Effect of Light Exposure During Acute Rehabilitation on Sleep After TBI
TWILIGHT: Effect of Light Exposure During Acute Rehabilitation on Sleep After TBI.
Status: Enrolling
Updated: 11/21/2017
Harborview Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis
Phase I Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis.
Status: Enrolling
Updated:  11/21/2017
Nationwide Children's Hospital
mi
from
Columbus, OH
Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis
Phase I Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis.
Status: Enrolling
Updated: 11/21/2017
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Clinical Intramuscular Gene Transfer Trial of rAAVrh74.MCK.Micro-Dystrophin to Patients With Duchenne Muscular Dystrophy
Phase I Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.Micro-dystrophin
Status: Enrolling
Updated:  11/21/2017
Nationwide Children's Hospital
mi
from
Columbus, OH
Clinical Intramuscular Gene Transfer Trial of rAAVrh74.MCK.Micro-Dystrophin to Patients With Duchenne Muscular Dystrophy
Phase I Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.Micro-dystrophin
Status: Enrolling
Updated: 11/21/2017
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Imatinib Mesylate to Treat Skin Changes in Patients With Chronic Graft-Versus-Host Disease
A Pilot Study of Imatinib Mesylate in Children and Adults With Sclerotic Skin Changes of Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated:  11/22/2017
National Cancer Institute , 9000 Rockville Pike
mi
from
Bethesda, MD
Imatinib Mesylate to Treat Skin Changes in Patients With Chronic Graft-Versus-Host Disease
A Pilot Study of Imatinib Mesylate in Children and Adults With Sclerotic Skin Changes of Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated: 11/22/2017
National Cancer Institute , 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis
Study NOG112264, a Phase II Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  11/27/2017
GSK Investigational Site
mi
from
Boston, MA
Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis
Study NOG112264, a Phase II Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 11/27/2017
GSK Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis
Study NOG112264, a Phase II Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  11/27/2017
GSK Investigational Site
mi
from
Grand Rapids, MI
Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis
Study NOG112264, a Phase II Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 11/27/2017
GSK Investigational Site
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis
Study NOG112264, a Phase II Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  11/27/2017
GSK Investigational Site
mi
from
Syracuse, NY
Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis
Study NOG112264, a Phase II Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 11/27/2017
GSK Investigational Site
mi
from
Syracuse, NY
Click here to add this to my saved trials
Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis
Study NOG112264, a Phase II Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  11/27/2017
GSK Investigational Site
mi
from
Columbus, OH
Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis
Study NOG112264, a Phase II Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 11/27/2017
GSK Investigational Site
mi
from
Columbus, OH
Click here to add this to my saved trials
Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis
Study NOG112264, a Phase II Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  11/27/2017
GSK Investigational Site
mi
from
Randwick,
Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis
Study NOG112264, a Phase II Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 11/27/2017
GSK Investigational Site
mi
from
Randwick,
Click here to add this to my saved trials
Multimodal Treatment of Phonological Alexia: Behavioral & fMRI Outcomes
Multimodal Treatment of Phonological Alexia: Behavioral & fMRI Outcomes
Status: Enrolling
Updated:  11/28/2017
North Florida/South Georgia Veterans Health System
mi
from
Gainesville, FL
Multimodal Treatment of Phonological Alexia: Behavioral & fMRI Outcomes
Multimodal Treatment of Phonological Alexia: Behavioral & fMRI Outcomes
Status: Enrolling
Updated: 11/28/2017
North Florida/South Georgia Veterans Health System
mi
from
Gainesville, FL
Click here to add this to my saved trials
Cognitive Enhancement Therapy for Adult Autism Spectrum Disorder
Cognitive Enhancement Therapy for Adult Autism Spectrum Disorder
Status: Enrolling
Updated:  11/28/2017
University of Pittsburgh
mi
from
Pittsburgh, PA
Cognitive Enhancement Therapy for Adult Autism Spectrum Disorder
Cognitive Enhancement Therapy for Adult Autism Spectrum Disorder
Status: Enrolling
Updated: 11/28/2017
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
mi
from
Glendale, AZ
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
mi
from
Glendale, AZ
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
mi
from
Glendale, AZ
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
mi
from
Glendale, AZ
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
mi
from
Mesa, AZ
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
mi
from
Mesa, AZ
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
mi
from
La Palma, CA
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
mi
from
La Palma, CA
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
mi
from
Granger, IN
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
mi
from
Granger, IN
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
mi
from
Saint Louis, MO
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
mi
from
Saint Louis, MO
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
mi
from
Orchard Park, NY
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
mi
from
Orchard Park, NY
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
mi
from
Salisbury, NC
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
mi
from
Salisbury, NC
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
mi
from
Middleburg Heights, OH
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
mi
from
Middleburg Heights, OH
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
mi
from
Duncansville, PA
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
mi
from
Duncansville, PA
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
mi
from
Austin, TX
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
mi
from
Houston, TX
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Site Reference ID/Investigator# 128791
mi
from
Maroochydore,
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Site Reference ID/Investigator# 128791
mi
from
Maroochydore,
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Medical Center of Aurora
mi
from
Aurora, CO
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Medical Center of Aurora
mi
from
Aurora, CO
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Boulder Community Hospital
mi
from
Boulder, CO
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Boulder Community Hospital
mi
from
Boulder, CO
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Rocky Mountain Cancer Centers - Boulder
mi
from
Boulder, CO
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Rocky Mountain Cancer Centers - Boulder
mi
from
Boulder, CO
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Rocky Mountain Cancer Centers-Penrose
mi
from
Colorado Springs, CO
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Rocky Mountain Cancer Centers-Penrose
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Penrose-Saint Francis Healthcare
mi
from
Colorado Springs, CO
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Penrose-Saint Francis Healthcare
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Rose Medical Center
mi
from
Denver, CO
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Rose Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Rocky Mountain Cancer Centers - Midtown
mi
from
Denver, CO
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Rocky Mountain Cancer Centers - Midtown
mi
from
Denver, CO
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Rocky Mountain Cancer Centers-Rose
mi
from
Denver, CO
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Rocky Mountain Cancer Centers-Rose
mi
from
Denver, CO
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Porter Adventist Hospital
mi
from
Denver, CO
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Porter Adventist Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Colorado Blood Cancer Institute
mi
from
Denver, CO
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Colorado Blood Cancer Institute
mi
from
Denver, CO
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Mercy Medical Center
mi
from
Durango, CO
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Mercy Medical Center
mi
from
Durango, CO
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Swedish Medical Center
mi
from
Englewood, CO
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Swedish Medical Center
mi
from
Englewood, CO
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Comprehensive Cancer Care and Research Institute of Colorado LLC
mi
from
Englewood, CO
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Comprehensive Cancer Care and Research Institute of Colorado LLC
mi
from
Englewood, CO
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Poudre Valley Hospital
mi
from
Fort Collins, CO
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Poudre Valley Hospital
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Mountain Blue Cancer Care Center
mi
from
Golden, CO
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Mountain Blue Cancer Care Center
mi
from
Golden, CO
Click here to add this to my saved trials